Anifrolumab for Systemic Lupus Erythematosus: A Clinical Study of Japanese Patients at Kanazawa University Hospital

This study at Kanazawa University Hospital evaluated the effectiveness of anifrolumab in treating systemic lupus erythematosus (SLE) in 7 Japanese patients. The patients, predominantly female, had a median age of 48 years and had been living with SLE for a median of 234 months before starting treatment. Anifrolumab treatment led to a median 100% decrease in both the SLE disease activity index (SLEDAI-2 K) and cutaneous lupus erythematosus disease area and severity index (CLASI) scores, indicating significant improvement in disease and skin symptoms. Additionally, patients were able to reduce their oral corticosteroid dosage. One patient discontinued due to uncontrolled pleurisy and pericarditis, but overall, anifrolumab proved effective in managing SLE symptoms and reducing corticosteroid dependency.